TRIUMPH program trial design overview — all Phase 3 arms
Posting this as an important update for the retatrutide & triple agonists community. Please read carefully as this may affect your current plans.
I will keep this thread updated as new information becomes available. If you have additional information or corrections, please post below and I will incorporate confirmed updates into this OP.
Key points:
Bookmarking this thread is recommended — it will be updated as the situation evolves.
TrialTracker_MD said:TRIUMPH program trial design overview — all Phase 3 arms Posting this as an important update for the retatrutide & triple agonists community.
Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale. Triple agonism means three receptor systems generating adverse events, and the dropout column is the one I would read first when the larger trials report.
TrialTracker_MD said:TRIUMPH program trial design overview — all Phase 3 arms Posting this as an important update for the retatrutide & triple agonists community.
I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemAnswering the narrow version, because the broad one does not have a single answer. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.
Dr.NutriCornell said:Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale.
Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.
If somebody has the primary source to hand I would rather cite it than paraphrase it.